71 related articles for article (PubMed ID: 94568)
1. Comparison of several in vitro assay methods for the quantitative determination of complement consumption ('binding') by gammaglobulin preparations.
Seiler FR; Peukert A; Kanzy EJ
Dev Biol Stand; 1979; 44():153-63. PubMed ID: 94568
[TBL] [Abstract][Full Text] [Related]
2. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
3. Reactions of immunoglobulin G-binding ligands with platelets and platelet-associated immunoglobulin G.
Rosse WF; Devine DV; Ware R
J Clin Invest; 1984 Feb; 73(2):489-96. PubMed ID: 6699173
[TBL] [Abstract][Full Text] [Related]
4. Fixation of the first component of complement (C'la) by human antibodies.
Rosse WF
J Clin Invest; 1969 Nov; 47(11):2430-45. PubMed ID: 4180276
[TBL] [Abstract][Full Text] [Related]
5. Purity, anticomplementary activity, and viral antibody profile of NIG preparations for intravenous and intramuscular use.
Scheiermann N; Kuwert EK
Dev Biol Stand; 1979; 44():165-71. PubMed ID: 544291
[TBL] [Abstract][Full Text] [Related]
6. Possible mechanisms of the first step of the classical complement activation pathway: binding and activation of C1.
Füst G; Medgyesi GA; Rajnavölgyi E; Csécsi-Nagy M; Czikora K; Gergely J
Immunology; 1978 Dec; 35(6):873-84. PubMed ID: 104923
[TBL] [Abstract][Full Text] [Related]
7. Assay of anticomplementary activity in solutions of immunoglobulins.
Römer J; Gardi A; Kistler P
Dev Biol Stand; 1979; 44():147-51. PubMed ID: 544290
[TBL] [Abstract][Full Text] [Related]
8. Final report of the safety assessment of Alcohol Denat., including SD Alcohol 3-A, SD Alcohol 30, SD Alcohol 39, SD Alcohol 39-B, SD Alcohol 39-C, SD Alcohol 40, SD Alcohol 40-B, and SD Alcohol 40-C, and the denaturants, Quassin, Brucine Sulfate/Brucine, and Denatonium Benzoate.
Cosmetic Ingredient Review Expert Panel
Int J Toxicol; 2008; 27 Suppl 1():1-43. PubMed ID: 18569160
[TBL] [Abstract][Full Text] [Related]
9. The effect of specific antibody on antibody-independent interactions between E. coli J5 and human complement.
Betz SJ; Page N; Estrade C; Isliker H
J Immunol; 1982 Feb; 128(2):707-11. PubMed ID: 7033382
[TBL] [Abstract][Full Text] [Related]
10. Activation of the complement attack mechanism in the fluid phase and its control by C567-INH: lysis of normal erythrocytes initiated by zymosan, endotoxin, and immune complexes.
Lint TF; Behrends CL; Baker PJ; Gewurz H
J Immunol; 1976 Nov; 117(5 Pt 1):1440-6. PubMed ID: 1002985
[TBL] [Abstract][Full Text] [Related]
11. Importance of the integrity of the inter-heavy-chain disulphide bond of rabbit IgG in the activation of the alternative pathway of human complement by the F(ab')2 region of rabbit IgG antibody in immune aggregates.
Gadd KJ; Reid KB
Immunology; 1981 Jan; 42(1):75-82. PubMed ID: 6780451
[TBL] [Abstract][Full Text] [Related]
12. Activation of C1 by soluble IgG aggregates as detected by a novel one-step hemolytic assay that specifically measures the proenzyme form of C1s.
Doekes G; van Es LA; Daha MR
J Immunol; 1983 Oct; 131(4):1924-9. PubMed ID: 6604753
[TBL] [Abstract][Full Text] [Related]
13. Addition of a mu-tailpiece to IgG results in polymeric antibodies with enhanced effector functions including complement-mediated cytolysis by IgG4.
Smith RI; Coloma MJ; Morrison SL
J Immunol; 1995 Mar; 154(5):2226-36. PubMed ID: 7868896
[TBL] [Abstract][Full Text] [Related]
14. Role of antibody and complement in the immune clearance and destruction of erythrocytes. II. Molecular nature of IgG and IgM complement-fixing sites and effects of their interaction with serum.
Schreiber AD; Frank MM
J Clin Invest; 1972 Mar; 51(3):583-9. PubMed ID: 4622104
[TBL] [Abstract][Full Text] [Related]
15. Interaction of peptidoglycans with anti-IgGs and with complement.
Bokisch VA
Z Immunitatsforsch Exp Klin Immunol; 1975 Jul; 149(2-4):320-30. PubMed ID: 126565
[TBL] [Abstract][Full Text] [Related]
16. Measurement of anticomplementary activity in therapeutic intravenous immunoglobulin preparations.
Ramasamy I; Tran E; Farrugia A
Biologicals; 1997 Mar; 25(1):87-92. PubMed ID: 9167012
[TBL] [Abstract][Full Text] [Related]
17. Binding and complement activation by C-reactive protein via the collagen-like region of C1q and inhibition of these reactions by monoclonal antibodies to C-reactive protein and C1q.
Jiang HX; Siegel JN; Gewurz H
J Immunol; 1991 Apr; 146(7):2324-30. PubMed ID: 2005402
[TBL] [Abstract][Full Text] [Related]
18. Evidence of persistent IgA/IgG circulating immune complexes associated with activation of the complement system in serum of a patient with common variable immune deficiency: anaphylactic reactions to intravenous gammaglobulin.
Wahn V; Good RA; Gupta S; Pahwa S; Day NK
Acta Pathol Microbiol Immunol Scand Suppl; 1984; 284():49-58. PubMed ID: 6203331
[TBL] [Abstract][Full Text] [Related]
19. The structure and function of immunoglobulin domains. IV. The distribution of some effector functions among the Cgamma2 and Cgamma3 homology regions of human immunoglobulin G1.
Yasmeen D; Ellerson JR; Dorrington KJ; Painter RH
J Immunol; 1976 Feb; 116(2):518-26. PubMed ID: 814165
[TBL] [Abstract][Full Text] [Related]
20. Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells.
Wright A; Morrison SL
J Immunol; 1998 Apr; 160(7):3393-402. PubMed ID: 9531299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
